Capstone Investment Advisors Portfolio holdings
AUM
$11.7B
1-Year Return
2.17%
This Quarter Return
-3.42%
1 Year Return
+2.17%
3 Year Return
+4.2%
5 Year Return
+5.2%
10 Year Return
+27.16%
AUM
$10.9B
AUM Growth
+$745M
(+7.4%)
Cap. Flow
-$836M
Cap. Flow
% of AUM
-7.7%
Top 10 Holdings %
Top 10 Hldgs %
60.99%
Holding
909
New
114
Increased
152
Reduced
156
Closed
325
Top Buys
| 1 |
Tesla
TSLA
|
$1.38B |
| 2 |
NVIDIA
NVDA
|
$721M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
$509M |
| 4 |
Apple
AAPL
|
$263M |
| 5 |
Amazon
AMZN
|
$212M |
Top Sells
| 1 |
Vanguard S&P 500 ETF
VOO
|
$1.09B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
$549M |
| 3 |
Microsoft
MSFT
|
$468M |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
$175M |
| 5 |
Intel
INTC
|
$96.1M |
Sector Composition
| 1 | Consumer Discretionary | 26.04% |
| 2 | Technology | 25.95% |
| 3 | Communication Services | 8.03% |
| 4 | Industrials | 2.26% |
| 5 | Financials | 2.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Cerence
CRNC
$399M
| $204K | ﹤0.01% |
25,787
-7,368
| -22% | -$58.2K |
|
402
Knight Transportation
KNX
$7B
| $201K | ﹤0.01% |
4,616
-191,161
| -98% | -$8.31M |
|
403
Viatris
VTRS
$12.2B
| $188K | ﹤0.01% |
21,536
-33,429
| -61% | -$291K |
|
|
WBA
404
DELISTED
Walgreens Boots Alliance
WBA
| $178K | ﹤0.01% |
15,965
-29,452
| -65% | -$329K |
|
405
Cardiff Oncology
CRDF
$144M
| $161K | ﹤0.01% |
51,190
| – | – |
|
406
Clover Health Investments
CLOV
$1.41B
| $154K | ﹤0.01% |
+42,897
| New | +$154K |
|
407
Wolfspeed
WOLF
$196M
| $103K | ﹤0.01% |
33,800
+33,455
| +9,697% | +$102K |
|
408
FerroAtlántica
GSM
$799M
| $93.8K | ﹤0.01% |
+25,270
| New | +$93.8K |
|
409
Eos Energy Enterprises
EOSE
$2.01B
| $91.4K | ﹤0.01% |
+24,187
| New | +$91.4K |
|
|
NESR
410
National Energy Services Reunited Corp. Ordinary Shares
NESR
$952M
| $86.6K | ﹤0.01% |
+11,764
| New | +$86.6K |
|
411
Red Cat Holdings
RCAT
$850M
| $77.4K | ﹤0.01% |
+13,167
| New | +$77.4K |
|
|
ALMS
412
Alumis Inc. Common Stock
ALMS
$469M
| $71.4K | ﹤0.01% |
+11,630
| New | +$71.4K |
|
413
Butterfly Network
BFLY
$393M
| $69.9K | ﹤0.01% |
+30,666
| New | +$69.9K |
|
414
Gevo
GEVO
$404M
| $60.3K | ﹤0.01% |
+51,974
| New | +$60.3K |
|
415
Ironwood Pharmaceuticals
IRWD
$188M
| $58.8K | ﹤0.01% |
+40,000
| New | +$58.8K |
|
416
Emergent Biosolutions
EBS
$404M
| $57.5K | ﹤0.01% |
+11,840
| New | +$57.5K |
|
417
Amylyx Pharmaceuticals
AMLX
$910M
| $57.2K | ﹤0.01% |
+16,150
| New | +$57.2K |
|
|
ATYR
418
aTyr Pharma
ATYR
$550M
| $55.6K | ﹤0.01% |
+18,420
| New | +$55.6K |
|
419
Opendoor
OPEN
$4.89B
| $51K | ﹤0.01% |
50,000
| – | – |
|
420
Microvast
MVST
$829M
| $47.1K | ﹤0.01% |
+40,236
| New | +$47.1K |
|
421
Citizens
CIA
$262M
| $46.3K | ﹤0.01% |
+10,184
| New | +$46.3K |
|
422
Eledon Pharmaceuticals
ELDN
$162M
| $46.1K | ﹤0.01% |
+13,613
| New | +$46.1K |
|
423
United States Antimony
UAMY
$561M
| $41.5K | ﹤0.01% |
+18,858
| New | +$41.5K |
|
424
Corvus Pharmaceuticals
CRVS
$459M
| $40.2K | ﹤0.01% |
+12,644
| New | +$40.2K |
|
425
Protalix BioTherapeutics
PLX
$123M
| $39.3K | ﹤0.01% |
+15,336
| New | +$39.3K |
|